Actavis, a global leader in the generic pharmaceuticals industry, yesterday announced it has entered into a binding letter of intent with QRxPharma to launch MoxDuo® IR in the United States.  Read the full story

Iceland-based generic pharmaceuticals company, Actavis has recently acquired 100% of the shares of the Dutch pharmaceutical packing manufacturer PharmaPack International B.V., a specialist in packaging pharmaceutical and biotechnological products. Read the full story

It has been reported that generic pharmaceuticals manufacturer, Actavis was able to deliver 10 million Levothyroxine tablets to Japan in order to help supply the shortage of Levothyroxine after the devastating earthquake on 11th March – these tablets were produced and delivered within only twenty days after requested for the treatment of thyroid problems. Read the full story

According to German media, the Icelandic generic company, Actavis is currently planning its expansion through future acquisitions. CEO at Actavis, Claudio Albrecht is reported to have said “we [Actavis] want to grow in the coming years by an average of ten to twelve percent – faster than the current growth of the market itself.” Read the full story

According to the German media channel Wirtschaftswoche, jobs losses at the pharmaceutical company, Ratiopharm would have been greatly reduced if Actavis, with newly appointed CEO Claudio Albrecht, would have been given the ‘go ahead’ to acquire the company. Read the full story

Icelandic businessman Bjorgolfur Thor Bjorgolfsson laid huge emphasis on keeping ownership of his Reykjavik house on Frikirkjuvegur when refinancing ISK 1,200 billion of debt recently. The house was build by his great grandfather a century ago. Read the full story

Actavis Group, the international generic pharmaceuticals company headquartered in Iceland, yesterday announced it has successfully agreed a debt refinancing in collaboration with its lenders. Read the full story

Actavis Group, the international generic pharmaceuticals company, today announced the appointment of former Ratiopharm leader Dr. Claudio Albrecht as its new CEO.

Read the full story

(Press release): Actavis Group, the international generic pharmaceuticals company, today announced plans to expand its manufacturing site in Iceland, increasing capacity at the site by 50%. Fifty new jobs will be created as a result. Read the full story

The product, Atorvastatin Magnesium, has been launched by four of Spain’s largest generic pharmaceutical companies. Actavis recently announced that its third-party sales division, Medis, has delivered around 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market and distribution to Spanish pharmacies has already commenced. Read the full story